CytoMed Therapeutics Limited

NasdaqCM:GDTC Stock Report

Market Cap: US$25.4m

CytoMed Therapeutics Valuation

Is GDTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GDTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GDTC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GDTC's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GDTC?

Key metric: As GDTC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for GDTC. This is calculated by dividing GDTC's market cap by their current book value.
What is GDTC's PB Ratio?
PB Ratio3.5x
BookS$10.16m
Market CapS$34.23m

Price to Book Ratio vs Peers

How does GDTC's PB Ratio compare to its peers?

The above table shows the PB ratio for GDTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.1x
BOLT Bolt Biotherapeutics
0.3x2.6%US$21.7m
GOVX GeoVax Labs
3.3x65.9%US$25.5m
MRKR Marker Therapeutics
3.7x-38.9%US$26.3m
SRZN Surrozen
5.2x-12.2%US$30.2m
GDTC CytoMed Therapeutics
3.5x10.2%US$25.4m

Price-To-Book vs Peers: GDTC is expensive based on its Price-To-Book Ratio (3.5x) compared to the peer average (3.1x).


Price to Book Ratio vs Industry

How does GDTC's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
ACET Adicet Bio
0.4x6.7%US$75.31m
MGX Metagenomi
0.3x-23.2%US$68.11m
GDTC 3.5xIndustry Avg. 1.9xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: GDTC is expensive based on its Price-To-Book Ratio (3.5x) compared to the US Biotechs industry average (1.8x).


Price to Book Ratio vs Fair Ratio

What is GDTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GDTC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GDTC's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies